Vito Quaranta
Overview
Explore the profile of Vito Quaranta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
114
Citations
4474
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Groves S, Ildefonso G, McAtee C, Ozawa P, Ireland A, Stauffer P, et al.
Cell Syst
. 2022 Aug;
13(9):690-710.e17.
PMID: 35981544
Small cell lung cancer (SCLC) tumors comprise heterogeneous mixtures of cell states, categorized into neuroendocrine (NE) and non-neuroendocrine (non-NE) transcriptional subtypes. NE to non-NE state transitions, fueled by plasticity, likely...
12.
Kenchappa R, Dovas A, Argenziano M, Meyer C, Stopfer L, Banu M, et al.
Cell Rep
. 2022 Jun;
39(12):110991.
PMID: 35732128
Inhibitors of the mitotic kinesin Kif11 are anti-mitotics that, unlike vinca alkaloids or taxanes, do not disrupt microtubules and are not neurotoxic. However, development of resistance has limited their clinical...
13.
Quaranta V, Linkous A
Front Oncol
. 2022 May;
12:881989.
PMID: 35574308
Small Cell Lung Cancer (SCLC) is a highly aggressive, neuroendocrine tumor. Traditional reductionist approaches have proven ineffective to ameliorate the uniformly dismal outcomes for SCLC - survival at 5 years...
14.
Wandishin C, Robbins C, Tyson D, Harris L, Quaranta V
Cancer Biol Ther
. 2022 Apr;
23(1):358-368.
PMID: 35443861
The drug-induced proliferation (DIP) rate is a metric of drug response that avoids inherent biases in commonly used metrics such as 72 h viability. However, DIP rate measurements rely on...
15.
Wooten D, Meyer C, Lubbock A, Quaranta V, Lopez C
Nat Commun
. 2021 Jul;
12(1):4607.
PMID: 34326325
Drug combination discovery depends on reliable synergy metrics but no consensus exists on the correct synergy criterion to characterize combined interactions. The fragmented state of the field confounds analysis, impedes...
16.
Rundo L, Tangherloni A, Tyson D, Betta R, Militello C, Spolaor S, et al.
Appl Sci (Basel)
. 2021 Jul;
10(18).
PMID: 34306736
Advances in microscopy imaging technologies have enabled the visualization of live-cell dynamic processes using time-lapse microscopy imaging. However, modern methods exhibit several limitations related to the training phases and to...
17.
Hayford C, Tyson D, Robbins 3rd C, Frick P, Quaranta V, Harris L
PLoS Biol
. 2021 Jun;
19(6):e3000797.
PMID: 34061819
Tumor heterogeneity is a primary cause of treatment failure and acquired resistance in cancer patients. Even in cancers driven by a single mutated oncogene, variability in response to targeted therapies...
18.
Lubbock A, Harris L, Quaranta V, Tyson D, Lopez C
Nucleic Acids Res
. 2021 May;
49(W1):W633-W640.
PMID: 34038546
High-throughput cell proliferation assays to quantify drug-response are becoming increasingly common and powerful with the emergence of improved automation and multi-time point analysis methods. However, pipelines for analysis of these...
19.
Olsen R, Ireland A, Kastner D, Groves S, Spainhower K, Pozo K, et al.
Genes Dev
. 2021 May;
35(11-12):847-869.
PMID: 34016693
ASCL1 is a neuroendocrine lineage-specific oncogenic driver of small cell lung cancer (SCLC), highly expressed in a significant fraction of tumors. However, ∼25% of human SCLC are ASCL1-low and associated...
20.
Thomas P, Groves S, Zhang Y, Li J, Gonzalez-Ericsson P, Sivagnanam S, et al.
J Thorac Oncol
. 2021 Apr;
16(7):1211-1223.
PMID: 33839362
Introduction: The programmed death-ligand 1 (PD-L1) immune checkpoint inhibitors, atezolizumab and durvalumab, have received regulatory approval for the first-line treatment of patients with extensive-stage SCLC. Nevertheless, when used in combination...